This retrospective matched cohort study analyzed patients with advanced HCC receiving either donafenib combined with PD-1 inhibitors or regorafenib combined with PD-1 inhibitors as second-line treatment after bevacizumab plus immunotherapy failure (2021-2024). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.